Hydrolysis of cis- and trans-epoxyeicosatrienoic acids by rat red blood cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 326, Issue 1, 2008, Pages 330-337

  Jiang, Houli ^a   Zhu, Angela G ^a   Mamczur, Magdalena ^a   Morisseau, Christophe ^b   Hammock, Bruce D ^b   Falck, John R ^c   McGiff, John C ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DICYCLOHEXYLUREA; 11,12 EPOXY 5,8,14 ICOSATRIENOIC ACID; 14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; 4 [4 (3 ADAMANTAN 1 YLUREIDO)CYCLOHEXYLOXY]BENZOIC ACID; 5,6 EPOXY 8,11,14 ICOSATRIENOIC ACID; 8,9 EPOXYICOSATRIENOIC ACID; BOVINE SERUM ALBUMIN; BUFFER; ENZYME INHIBITOR; EPOXIDE HYDROLASE; EPOXIDE HYDROLASE INHIBITOR; EPOXYICOSATRIENOIC ACID;

ANIMAL CELL; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CIS ISOMER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOSOL; ENZYME ACTIVITY; ENZYME INHIBITION; ERYTHROCYTE; GEOMETRY; HYDRATION; HYDROLYSIS; ICOSANOID METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOCHEMISTRY; TRANS ISOMER; WESTERN BLOTTING;

ANIMALS; ERYTHROCYTES; HYDROLYSIS; HYDROXYEICOSATETRAENOIC ACIDS; MALE; MOLECULAR CONFORMATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 45749147793     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.134858     Document Type: Article

References (41)

1. Ai D, Fu Y, Guo D, Tanaka H, Wang N, Tang C, Hammock BD, Shyy JY, and Zhu Y (2007) Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci U S A 104:9018-9023.
2. Capdevila JH, Dishman E, Karara A, and Falck JR (1991) Cytochrome P450 arachidonic acid epoxygenase: stereochemical characterization of epoxyeicosatrienoic acids. Methods Enzymol 206:441-453.
3. Chacos N, Capdevila J, Falck JR, Manna S, Martin-Wixtrom C, Gill SS, Hammock BD, and Estabrook RW (1983) The reaction of arachidonic acid epoxides (epoxyeicosatrienoic acids) with a cytosolic epoxide hydrolase. Arch Biochem Biophys 223:639-648.
4. Davis BB, Thompson DA, Howard LL, Morisseau C, Hammock BD, and Weiss RH (2002) Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc Natl Acad Sci U S A 99:2222-2227.
5. Falck JR, Krishna UM, Reddy YK, Kumar PS, Reddy KM, Hittner SB, Deeter C, Sharma KK, Gauthier KM, and Campbell WB (2003) Comparison of vasodilatory properties of 14,15-EET analogs: structural requirements for dilation. Am J Physiol Heart Circ Physiol 284:H337-H349.
6. Fleming I (2007) Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins Other Lipid Mediat 82:60-67.
7. Ghosh S, Chiang PC, Wahlstrom JL, Fujiwara H, Selbo JG, and Roberds SL (2008) Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats. Basic Clin Pharmacol Toxicol 102:453-458.
8. Grant DF, Storms DH, and Hammock BD (1993) Molecular cloning and expression of murine liver soluble epoxide hydrolase. J Biol Chem 268:17628-17633.
9. Hwang SH, Tsai HJ, Liu JY, Morisseau C, and Hammock BD (2007) Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem 50:3825-3840.
10. Imig JD (2005) Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol 289:F496-F503.
11. Imig JD, Zhao X, Capdevila JH, Morisseau C, and Hammock BD (2002) Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39:690-694.
12. Inceoglu B, Schmelzer KR, Morisseau C, Jinks SL, and Hammock BD (2007) Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat 82:42-49.
13. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
14. Jiang H, McGiff JC, Quilley J, Sacerdoti D, Reddy LM, Falck JR, Zhang F, Lerea KM, and Wong PY (2004) Identification of 5,6-trans-epoxyeicosatrienoic acid in the phospholipids of red blood cells. J Biol Chem 279:36412-36418.
15. Jiang H, Quilley J, Reddy LM, Falck JR, Wong PY, and McGiff JC (2005) Red blood cells: reservoirs of cis- and trans-epoxyeicosatrienoic acids. Prostaglandins Other Lipid Mediat 75:65-78.
16. Jiang H, Zhu AG, Mamczur M, Falck JR, Lerea KM, and McGiff JC (2007) Stimulation of rat erythrocyte P2X(7) receptor induces the release of epoxyeicosatrienoic acids. Br J Pharmacol 151:1033-1040.
17. Karara A, Wei S, Spady D, Swift L, Capdevila JH, and Falck JR (1992) Arachidonic acid epoxygenase: structural characterization and quantification of epoxyeicosatrienoates in plasma. Biochem Biophys Res Commun 182:1320-1325.
18. Larsen BT, Gutterman DD, and Hatoum OA (2006) Emerging role of epoxyeicosatrienoic acids in coronary vascular function. Eur J Clin Invest 36:293-300.
19. Liu Y, Zhang Y, Schmelzer K, Lee TS, Fang X, Zhu Y, Spector AA, Gill S, Morisseau C, Hammock BD, et al. (2005) The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci U S A 102:16747-16752.
20. Loch D, Hoey A, Morisseau C, Hammock BO, and Brown L (2007) Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem Biophys 47:87-98.
21. McElroy NR, Jurs PC, Morisseau C, and Hammock BD (2003) QSAR and classification of murine and human soluble epoxide hydrolase inhibition by urea-like compounds. J Med Chem 46:1066-1080.
22. McGee J and Fitzpatrick F (1985) Enzymatic hydration of leukotriene A4. Purification and characterization of a novel epoxide hydrolase from human erythrocytes. J Biol Chem 260:12832-12837.
23. Morisseau C and Hammock BD (2005) Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol 45:311-333.
24. Morisseau C and Hammock BD (2007) Measurements of soluble epoxide hydrolase (sEH) activity, in Techniques for Analysis of Chemical Biotransformation. Current Protocols in Toxicology (Bus JS, Costa LG, Hodgson E, Lawrence DA, and Reed DJ eds) pp 4.23.1- 4.23.18, John Wiley & Sons, New Jersey.
25. Nakamura T, Bratton DL, and Murphy RC (1997) Analysis of epoxyeicosatrienoic and monohydroxyeicosatetraenoic acids esterified to phospholipids in human red blood cells by electrospray tandem mass spectrometry. J Mass Spectrom 32:888-896.
26. Ota K and Hammock BD (1980) Cytosolic and microsomal epoxide hydrolases: differential properties in mammalian liver. Science 207:1479-1481.
27. Rodriguez M and Clare-Salzler M (2006) Eicosanoid imbalance in the NOD mouse is related to a dysregulation in soluble epoxide hydrolase and 15-PGDH expression. Ann N Y Acad Sci 1079:130-134.
28. Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP, and Hammock BD (2005) Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci U S A 102:9772-9777.
29. Seidegård J, DePierre JW, and Pero RW (1984) Measurement and characterization of membrane-bound and soluble epoxide hydrolase activities in resting mononuclear leukocytes from human blood. Cancer Res 44:3654-3660.
30. Seubert JM, Sinal CJ, Graves J, Degraff LM, Bradbury JA, Lee CR, Goralski K, Carey MA, Luria A, Newman JW, et al. (2006) Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res 99:442-450.
31. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, and Gonzalez FJ (2000) Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 275:40504-40510.
32. Smith KR, Pinkerton KE, Watanabe T, Pedersen TL, Ma SJ, and Hammock BD (2005) Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci U S A 102:2186-2191.
33. Starke DW, Blisard KS, and Mieyal JJ (1984) Substrate specificity of the monooxygenase activity of hemoglobin. Mol Pharmacol 25:467-475.
34. Thomas H, Schladt L, Doehmer J, Knehr M, and Oesch F (1990) Rat and human liver cytosolic epoxide hydrolases: evidence for multiple forms at level of protein and mRNA. Environ Health Perspect 88:49-55.
35. Wei S, Brittin JJ, Falck JR, Anjaiah S, Nithipatikom K, Cui L, Campbell WB, and Capdevila JH (2006) Chiral resolution of the epoxyeicosatrienoic acids, arachidonic acid epoxygenase metabolites. Anal Biochem 352:129-134.
36. Weintraub NL, Fang X, Kaduce TL, VanRollins M, Chatterjee P, and Spector AA (1999) Epoxide hydrolases regulate epoxyeicosatrienoic acid incorporation into coronary endothelial phospholipids. Am J Physiol Heart Circ Physiol 277:H2098-H2108.
37. Widstrom RL, Norris AW, Van Der Veer J, and Spector AA (2003) Fatty acid-binding proteins inhibit hydration of epoxyeicosatrienoic acids by soluble epoxide hydrolase. Biochemistry 42:11762-11767.
38. Yu Z, Davis BB, Morisseau C, Hammock BD, Olson JL, Kroetz DL, and Weiss RH (2004) Vascular localization of soluble epoxide hydrolase in the human kidney. Am J Physiol Renal Physiol 286:F720-F726.
39. Zeldin DC, Kobayashi J, Falck JR, Winder BS, Hammock BD, Snapper JR, and Capdevila JH (1993) Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. J Biol Chem 268:6402-6407.
40. Zeldin DC, Wei S, Falck JR, Hammock BD, Snapper JR, and Capdevila JH (1995) Metabolism of epoxyeicosatrienoic acids by cytosolic epoxide hydrolase: substrate structural determinants of asymmetric catalysis. Arch Biochem Biophys 316:443-451.
41. Zhang W, Koerner IP, Noppens R, Grafe M, Tsai HJ, Morisseau C, Luria A, Hammock BD, Falck JR, and Alkayed NJ (2007) Soluble epoxide hydrolase: a novel therapeutic target in stroke. J Cereb Blood Flow Metab 27:1931-1940.